Twenty-four-hour simultaneous subcutaneous Basal-bolus administration of insulin and amylin in adolescents with type 1 diabetes decreases postprandial hyperglycemia.

Heptulla RA, Rodriguez LM, Mason KJ, Haymond MW

The Journal of clinical endocrinology and metabolism3 Feb 2009Cited by 18 (Europe PMC)

PMID19190104PMCIDPMC2684475DOI10.1210/jc.2008-2580PepBankPUB-19190104

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adolescents with T1DM, pramlintide plus insulin with reduced prandial boluses reduced postprandial hyperglycemia compared with insulin monotherapy.
In plain wordsIn adolescents with T1DM, pramlintide plus insulin with reduced meal boluses lowered postmeal hyperglycemia compared with insulin alone.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial hyperglycemia
Study
n = 13
Comparator
Insulin monotherapy
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous infusion · 24 hAs given in this study (human).
Measurements
Postprandial hyperglycemia reduction
26%
study regimen versus insulin monotherapy
Postprandial AUC (600 min), first value of reported pair
2610 mg/liter . min
reported as '2610 +/- 539 vs. 692 +/- 861'; group order not stated
Postprandial AUC (600 min), second value of reported pair
692 mg/liter . min
reported as '2610 +/- 539 vs. 692 +/- 861'; group order not stated
Source sentences
Summary
The study regimen resulted in a 26% reduction in postprandial hyperglycemia as compared to insulin monotherapy (area under the curve, 600 min, 2610 +/- 539 vs. 692 +/- 861 mg/liter . min) (P < 0.008).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirteen adolescents with type 1 diabetes on insulin pump therapy participated in a randomized, controlled, crossover design study comparing continuous sc insulin monotherapy (part A) vs. continuous sc insulin and pramlintide infusion (part B).
Summary · context
In part B, the basal insulin infusion was the same as part A, but prandial insulin boluses were reduced by 20%.
Report a problemFND-1919010401
02HumanRandomized controlled trialEfficacy outcome
In adolescents with T1DM, the pramlintide-insulin regimen suppressed postprandial glucagon concentrations.
In plain wordsIn adolescents with T1DM, the pramlintide-insulin regimen suppressed postmeal glucagon compared with insulin alone.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial glucagon
Study
n = 13
Comparator
Insulin monotherapy
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous infusion · 24 hAs given in this study (human).
Source sentences
Summary
Glucagon concentrations were suppressed postprandially (P < 0.003) but not in the postabsorptive state, whereas plasma insulin concentrations were unchanged.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirteen adolescents with type 1 diabetes on insulin pump therapy participated in a randomized, controlled, crossover design study comparing continuous sc insulin monotherapy (part A) vs. continuous sc insulin and pramlintide infusion (part B).
Summary · context
In part B, the basal insulin infusion was the same as part A, but prandial insulin boluses were reduced by 20%.
Report a problemFND-1919010402
03HumanRandomized controlled trialEfficacy outcome
In adolescents with T1DM, the pramlintide-insulin regimen did not suppress postabsorptive glucagon concentrations.
In plain wordsIn adolescents with T1DM, the pramlintide-insulin regimen did not suppress glucagon after absorption compared with insulin alone.
Peptide
Pramlintide (Symlin)
Outcome
No significant changePostabsorptive glucagon
Study
n = 13
Comparator
Insulin monotherapy
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous infusion · 24 hAs given in this study (human).
Source sentences
Summary
Glucagon concentrations were suppressed postprandially (P < 0.003) but not in the postabsorptive state, whereas plasma insulin concentrations were unchanged.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirteen adolescents with type 1 diabetes on insulin pump therapy participated in a randomized, controlled, crossover design study comparing continuous sc insulin monotherapy (part A) vs. continuous sc insulin and pramlintide infusion (part B).
Summary · context
In part B, the basal insulin infusion was the same as part A, but prandial insulin boluses were reduced by 20%.
Report a problemFND-1919010403
04HumanRandomized controlled trialEfficacy outcome
In adolescents with T1DM, plasma insulin concentrations were unchanged with the pramlintide-insulin regimen.
In plain wordsIn adolescents with T1DM, plasma insulin stayed unchanged with the pramlintide-insulin regimen compared with insulin alone.
Peptide
Pramlintide (Symlin)
Outcome
No significant changePlasma insulin
Study
n = 13
Comparator
Insulin monotherapy
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous infusion · 24 hAs given in this study (human).
Source sentences
Summary
Glucagon concentrations were suppressed postprandially (P < 0.003) but not in the postabsorptive state, whereas plasma insulin concentrations were unchanged.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirteen adolescents with type 1 diabetes on insulin pump therapy participated in a randomized, controlled, crossover design study comparing continuous sc insulin monotherapy (part A) vs. continuous sc insulin and pramlintide infusion (part B).
Summary · context
In part B, the basal insulin infusion was the same as part A, but prandial insulin boluses were reduced by 20%.
Report a problemFND-1919010404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT00291772

Continuous Subcutaneous Infusion of Pramlintide and Insulin

Baylor College of Medicinen = 13Jan 2006 to Nov 2007

Type 1 Diabetes

Trial page ClinicalTrials.govUpdated 14 Jul 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.